ArticleScientific reports2025
Monitoring of antibodies against SARS-CoV-2 over 2 years and characterization of immune responses following Omicron infection in a South Indian community cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Multiple severe acute respiratory syndrome (SARS-CoV-2) exposures either due to infection or vaccination result in differential immune responses. Limited data exist on community-level SARS-CoV-2 variant exposures in India. We assessed antibody levels in 211 unvaccinated and 349 vaccinated individuals with and without prior exposure, followed for ~ 2 years (May 2021-October 2023) with baseline blood, weekly saliva for RT-PCR, and blood draws at ~ 6, 12, and 24 months. Humoral and cellular immune responses following primary (N = 8) and secondary (N = 11) Omicron infections in unvaccinated, previously exposed (N = 25), and unexposed vaccinated (N = 14) individuals were evaluated using Meso Scale Discovery and flow cytometry assays at Day 0, 30, and 90. Previously exposed individuals had higher anti-spike IgG levels at baseline (median 57,732 vs. 11,359, p < 0.001 in unvaccinated; 93,827 vs. 26,883, p < 0.001 in vaccinated) and 99% seropositivity at 2 years. Secondary Omicron infection elicited higher anti-spike IgG levels (17,320 vs. 3,930, p < 0.01) and stronger CD8 T cell responses (median CD8 AIM 0.026 vs. 0.001, p = 0.01 at Day90) than primary Omicron infection. Vaccinated individuals showed comparable CD4 and CD8 T cell responses irrespective of prior exposure, but previously exposed individuals had more durable antibodies at Day90 (p < 0.05 in previously exposed). Anti-spike IgG levels and %ACE-2 inhibition to Omicron were lower in both groups compared to other variants. High seropositivity was observed in both vaccinated and unvaccinated individuals after multiple exposures, though antibody levels were higher in individuals with prior exposure. These findings underscore preserved T cell responses to Omicron, although with lesser magnitude among unvaccinated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.